Faes Farma posted strong Q3 16 numbers. Total revenue was up 7% yoy in both Q3 16 and 9M 16 to €57.4m and €171.4m, respectively, mainly driven by Bilastine. Profitability remained strong – while Q3 16 EBIT increased 16% to €14.7m, net income was up 17% to €11.4m.
21 Nov 2016
Strong Q3; Bilastine launched in Japan
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong Q3; Bilastine launched in Japan
Faes Farma, S.A. (FFEA:FRA) | 0 0 2.0% | Mkt Cap: 765.7m
- Published:
21 Nov 2016 -
Author:
Jyoti Prakash -
Pages:
2
Faes Farma posted strong Q3 16 numbers. Total revenue was up 7% yoy in both Q3 16 and 9M 16 to €57.4m and €171.4m, respectively, mainly driven by Bilastine. Profitability remained strong – while Q3 16 EBIT increased 16% to €14.7m, net income was up 17% to €11.4m.